UBS’s AstraZeneca AZN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2014
Q3
$123M Sell
1,725,695
-47,642
-3% -$3.49M 0.09% 231
2014
Q2
$132M Sell
1,773,337
-603,292
-25% -$43.6M 0.1% 206
2014
Q1
$154M Sell
2,376,629
-658,957
-22% -$42.6M 0.14% 160
2013
Q4
$180M Sell
3,035,586
-2,636,788
-46% -$143M 0.17% 141
2013
Q3
$295M Buy
5,672,374
+440,846
+8% +$22.1M 0.3% 56
2013
Q2
$247M Buy
+5,231,528
New +$266M 0.29% 57

Other funds holding AZN

UBS's AZN Position: Q3 2014 in Review

UBS reduced its AstraZeneca (AZN) stake by 2.7% in Q3 2014, selling an estimated $3.49M and leaving 1,725,695 shares worth $123M. The position accounts for 0.09% of the portfolio, ranked #231.

UBS first reported a position in AZN in Q2 2013 and has held it in 6 quarters since. The position peaked at $295M in Q3 2013. 401 funds tracked by Wall St. Rank hold AZN as of Q3 2014.

  • UBS held 1,725,695 shares of AstraZeneca worth $123M as of Q3 2014.
  • UBS sold 47,642 AstraZeneca shares in Q3 2014, an estimated $3.49M.
  • AstraZeneca made up 0.09% of UBS's portfolio in Q3 2014, its #231 holding.
  • UBS first reported a position in AstraZeneca in Q2 2013 and has held it in 6 quarters since.
  • UBS's AstraZeneca position peaked at $295M in Q3 2013.
  • 401 funds tracked by Wall St. Rank held AstraZeneca as of Q3 2014.

Based on UBS's 13F filing for Q3 2014, filed 12 Nov 2014.